Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News What Are the New Weight Loss Medications? NowPatient VisualAbstract: Combined cagrilintide and semaglutide for weight management well tolerated in early clinical trials 2 Minute Medicine In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Targeting the weight within: obesity pharmacotherapy in cardiovascular disease Medicine Today CagriSema in Adults With or Without Diabetes REDEFINE 1 & 2 Cagrilintide 2.4 mg + Semaglutide 2.4 mg once weekly 20.4% weight loss (non diabetic) & 13.7% (T2D)